Effectiveness of hyperbaric oxygen in traumatic brain injury patients: A systematic review and meta-analysis.

Complement Ther MedAug 10, 2026 (epub)
Clinical ResearchNeurology

Haiming Wang, Hang Zhou, Jing Nie et al.

✦ AI-curated · Sources linked

In 30 seconds

This systematic review and meta-analysis evaluated the effectiveness of hyperbaric oxygen therapy (HBOT) in adults with traumatic brain injury (TBI). Analyzing data from 8 randomized controlled trials involving 570 participants, the study found that HBOT significantly improved cognitive performance (SMD = 0.23) and sleep quality (MD = 1.98), but showed no significant benefits for PTSD or neurobehavioral symptoms.

Key findings

  • HBOT significantly improved computerized cognitive performance (SMD = 0.23, p = 0.004).
  • Executive function and processing speed improved with HBOT (SMD = -0.59, p = 0.0005).
  • Memory function showed significant improvement (SMD = 0.33, p = 0.03).
  • No significant benefits were observed for PTSD symptoms (MD = -3.05, p = 0.04).

Why it matters

The findings suggest that HBOT may offer specific cognitive and sleep-related benefits for patients with mild TBI, which could influence treatment approaches in this population. However, the lack of significant effects on other important outcomes highlights the need for cautious interpretation.

Source

PubMed · PMID 42575227

Published in Complement Ther Med. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Neurology

Clinical ResearchHematology

Ponatinib-Blinatumomab or Imatinib-Chemotherapy for Adult Ph-Positive ALL.

This multicenter, phase 3 randomized trial compared frontline ponatinib plus blinatumomab with imatinib plus chemotherapy in adults with Philadelphia-positive acute lymphoblastic leukemia.

N Engl J MedOct 15, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary
Clinical ResearchRheumatology

Ianalumab for the Treatment of Patients with Sjögren's Disease.

Two 52-week, double-blind, randomized, placebo-controlled phase III trials evaluated monthly or less frequent ianalumab in patients with active Sjögren's disease.

N Engl J MedOct 22, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text
Create my personalized digestSee plans

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.